Tie-2 Activation for Restoring Endothelial Barrier Integrity in ARDS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for acute respiratory distress syndrome (ARDS) and conditions like COVID-19 primarily manage symptoms or underlying causes, failing to directly address the pathophysiology, leading to prolonged disease burden and suboptimal lung function recovery.
Innovation Solution
Administering a therapeutically-effective amount of a Tie-2 activator, such as a compound that inhibits HPTPβ/VE-PTP, to activate Tie-2 signaling, thereby restoring endothelial barrier integrity and reducing vascular permeability, inflammation, and improving oxygenation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies for ARDS are used to manage symptoms or underlying causes, then treatment can be provided, but the disease burden is prolonged and lung function recovery is suboptimal
Solution Approach 1:
The patent applies preliminary action by activating Tie-2 signaling pathway before severe endothelial damage occurs. The Tie-2 activator pre-emptively stabilizes endothelial barriers and reduces vascular permeability, preventing the progression to severe ARDS and reducing overall disease burden duration.
Solution Approach 2:
The patent uses Tie-2 activator as an intermediary substance that mediates between the inflammatory response and endothelial integrity. The activator binds to Tie-2 receptors on endothelial cells, triggering protective signaling cascades that maintain barrier function during inflammatory states, thereby improving treatment efficacy.
2Reliability
If Tie-2 activator is administered to restore endothelial barrier integrity, then vascular permeability and inflammation are reduced, but the complexity of the treatment mechanism increases
Solution Approach 1:
The patent applies parameter changes by modifying the activation state of the Tie-2 receptor through pharmacological intervention. The Tie-2 activator changes the signaling parameters of the endothelial cells, enhancing barrier function and reducing permeability through targeted molecular parameter modulation rather than complex mechanical interventions.
3Productivity
If Tie-2 activator is used to directly address pathophysiology, then lung function recovery is improved, but the specificity of targeting required increases
Solution Approach 1:
The Tie-2 activator serves as a specific intermediary that targets the Tie-2 receptor tyrosine kinase on endothelial cells. This targeted approach directly addresses the pathophysiology of ARDS by restoring endothelial barrier function through specific molecular interaction, improving lung function recovery while maintaining therapeutic specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Tie-2 activator increases the oxygenation index by 1 to 20 within 7 days, reducing the need for mechanical ventilation support and improving lung function by stabilizing the pulmonary endothelium, thus addressing the underlying pathophysiology of ARDS and COVID-19.
Implementation Method 1
Administering a therapeutically-effective amount of a Tie-2 activator, such as a compound that inhibits HPTPβ/VE-PTP, to activate Tie-2 signaling
Implementation Method 2
such as a compound that inhibits HPTPβ/VE-PTP
Data Source
AI summary
Disclosed herein are methods for treating acute respiratory distress syndrome, lung injury, respiratory failure, and associated conditions using activators of Tie-2 and inhibitors of HPTPβ. The methods include reducing vascular leak and permeability, reducing edema, reducing inflammation, and increasing oxygen exchange capacity in the lungs.